Zhejiang Hisun Pharmaceutical Co. Ltd. and Shanghai Aryl Pharmtech Co. Ltd. have identified heterocyclic derivatives acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
Investigators from Immunos Therapeutics AG aimed to develop novel anticancer therapies by using a reverse rational approach from HLA class I molecules with the aim to induce autoimmunity, and they identified HLA-B*57 as a well-known genetic factor associated with superior control of viral infections through processes not linked with peptide presentation.
Treatment with anti-PD-1 checkpoint inhibitors is not effective in all cases, and around 10% of melanoma patients actually experience a rapid deterioration, a phenomenon known as hyperprogressive disease. Some studies have linked hyperprogression to specific immune cell populations or genes, and it remains unclear if this complication can be directly attributed to checkpoint immunotherapy or not.
Constellation Pharmaceuticals Inc. has described three-prime repair exonuclease 1 (TREX1) inhibitors reported to be useful for the treatment of cancer.
Jiangsu Mabwell Health Pharmaceutical R&D Co. Ltd. and Mabwell (Shanghai) Bioscience Co. Ltd. have synthesized antibody-drug conjugates (ADCs) consisting of antibodies targeting nectin-4 covalently linked to cytotoxic drugs through a linker reported to be useful for treatment of cancer.
Jiangsu Simcere Pharmaceutical R&D Co. Ltd. has disclosed alkyne compounds acting as mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer.
Glioblastoma (GBM) is the most common type of primary brain tumor in adults, with only a 7% rate of 5-year overall survival for patients. Oncolytic viruses based on HSV-1 vectors are an interesting and to-explore area for GBM treatment.
Activation of the cGAS-STING pathway activates the immune system through the production of type I interferons. There is knowledge that myeloid cell populations are among the most sensitive to STING agonism. Investigators at Takeda Pharmaceutical Co. Ltd. presented results on TAK-500, an immune stimulant antibody-drug conjugate (ISAC) composed of an antibody linked to a STING agonist for delivery to CCR2+ cells.
Researchers from Sutro Biopharma Inc. presented the discovery and preclinical characterization of a novel receptor tyrosine kinase-like orphan receptor 1 (ROR1)-targeted antibody-drug conjugate (ADC), STRO-003, being developed for the treatment of cancer.
The Institute of Cancer Research (ICR) in London is shifting the focus of drug discovery from molecular targets in cancer cells to take in the whole ecosystem supporting tumor growth, evolution and the development of resistance. The aim is to exploit new understanding of the way cancers evolve within the ecosystem of the body, the interaction between cancer cells and the immune system, and the reliance of a tumor on the tissue and growth signals that surround it. Manipulating this environment could make cancer cells become “extinct,” ICR researchers say.
RSS
